| Symbol | NTHI |
|---|---|
| Name | NEONC TECHNOLOGIES HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 23975 PARK SORRENTO,SUITE 205, CALABASAS, California, 91302, United States |
| Telephone | +1 818-570-6844 |
| Fax | — |
| — | |
| Website | https://neonc.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001979414 |
| Description | Our company (NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Additional info from NASDAQ: |
(85% Positive) NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Provides Update on trial for recurrent IDH1 mutant high-grade glioma
Read moreThe Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
Read moreTargeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
Read more(70% Positive) NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Announces Enrollment Update for benchmark Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment
Read more(70% Positive) NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Announces Enrollment Update for approvals Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations
Read moreNeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears
Read moreNeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
Read moreNeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Read moreNeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
Read moreNeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Read more